Full-Time
Physiker / Ingenieur
Technisches Key Account Management, Optical Gratings & Spectrometers
Zeiss
1,001-5,000 employees
Manufactures high-precision optical instruments and devices
No salary listed
Jena, Germany + 1 more
More locations: Oberkochen, Germany
In Person
International travel of approximately 20% is required.
Bachelor's
 Sales & Account Management (1) |
|---|
Get referred to Zeiss
See people who can refer or advise you
- A completed degree in Physics, Chemistry, Engineering, or a comparable technical qualification, ideally specializing in optics or lasers.
- Several years of experience in technical business-to-business sales, key account management, or technical project management.
- Confidently navigate decision-making structures in larger organizations and have an interest in technical topics.
- Demonstrate a professional presence, clear communication, and a good understanding of market and customer potential.
- Be willing to travel approximately 20% for customer appointments and international events.
- Have very good German and English language skills at least at the C1 level.
- Strategically support and further develop customers in existing and new markets.
- Develop solutions with customers for their products in close cooperation with product specialists and product management.
- Conduct technical and commercial discussions with decision-makers at management and engineering levels, from inquiry through contract conclusion.
- Present the product portfolio at international trade fairs and conferences and explain how the technologies are applied.
- Contribute to long-term customer satisfaction and retention through versatility and innovation.
- Act as a central participant in interdisciplinary collaboration as a Key Account Manager.
- Promote information flow and coordination between teams such as product management and customer project management.
ZEISS is a global leader in optics and optoelectronics, serving medical professionals, industrial manufacturers, consumers, and the semiconductor industry. It designs and sells high-precision optical instruments, medical devices, semiconductor manufacturing equipment, and vision care products such as corrective lenses and eye-health services. Its products rely on advanced optics and imaging technologies to deliver accurate inspection, diagnosis, and manufacturing outcomes across healthcare, industrial quality control, consumer optics, and chip fabrication. What sets ZEISS apart is its breadth and depth: a long-standing scale in multiple markets, integrated solutions across optics, imaging, metrology, and precision engineering, and a commitment to sustainability in electricity use and carbon emissions. The company’s goal is to advance optics and optoelectronics by providing reliable, high-quality tools and services worldwide while operating in a sustainable way.
Company Size
1,001-5,000
Company Stage
Growth Equity (Non-Venture Capital)
Total Funding
$1.1B
Headquarters
Oberkochen, Germany
Founded
2001
Get referred to Zeiss
See people who can refer or advise you
Simplify's Take
What believers are saying
- ZEISS won Mexico COFEPRIS approval in 2026 for ARTEVO 850 and MICOR 700.
- ZEISS launched VisioGen commercially in the US at ASCRS 2026, expanding recurring software sales.
- August 6, 2026 meditec nine-month results showed stable currency-adjusted revenue momentum.
What critics are saying
- ZEISS announced June 9, 2026 cost cuts and expected job reductions across segments.
- Carl Zeiss Meditec targets over €200 million annual savings through 2028/29, signaling pressure.
- Medical Technology revenue fell 7% in first half fiscal 2025/26, exposing dependence on semiconductors.
What makes Zeiss unique
- Foundation-owned ZEISS spans semiconductors, ophthalmology, and metrology under one capital structure.
- ZEISS Semiconductor Manufacturing Technology grew 6% in first half fiscal 2025/26, driven by EUV optics.
- ZEISS owns the IOLMaster, ARTEVO, and FORUM workflow stack across cataract care.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
Paid Vacation
Performance Bonus
Growth & Insights and Company News
6 month growth
↑ 4%1 year growth
↑ 4%2 year growth
↑ 4%ZEISS Ventures led a €2.2 million investment round in SeeTrue Technologies, a Finnish deep-tech company developing miniaturised eye-tracking technology. The funding will accelerate commercialisation of SeeTrue's ultra-low-power eye-sensing architecture for next-generation interfaces in smart optical systems and eyewear. SeeTrue's proprietary technology combines miniaturised sensing hardware with optimised embedded processing, enabling scalable eye-sensing capabilities with low power consumption and small hardware footprint. The technology supports gaze-based interaction and attention-aware computing across healthcare, industrial, and smart eyewear applications. The investment round includes participation from Superhero Capital and North Karelia Growth Fund, managed by Redstone Nordics. Founded in 2018 and based in Joensuu, Finland, SeeTrue develops ultra-miniature eye-tracking technology for medical optical systems, vision care, and smart wearables.
ZEISS Medical Technology has announced successful early clinical implantations of its AT LUCIA toric 721P intraocular lens, designed to treat cataracts whilst correcting astigmatism. The company is conducting an early-access clinical trial with experienced surgeons across six European countries. The lens combines an aspheric bitoric optic with a patented non-constant aberration design on a fully preloaded, hydrophobic platform. Surgeons have reported positive early impressions, highlighting the lens's precision, stability and surgical handling. Currently CE marked, the AT LUCIA toric 721P will be showcased at the International Congress of German Ophthalmic Surgery in Nuremberg from 18–20 June 2026. The lens is expected to be commercially available in select European countries later this year.
ZEISS Ventures has invested in Maculaser, a Finnish medtech company developing temperature-controlled retinal laser therapy, through a funding round co-led with M2care. The investment will support clinical development of the company's personalized treatment for retinal diseases. Founded in 2020 and based on research from Aalto University, Maculaser has developed patented technology that provides real-time temperature control during laser treatment. The non-damaging approach activates natural cellular defence mechanisms, targeting affected retinal areas early to delay or prevent progression of age-related macular degeneration and diabetic maculopathy. The technology aims to shift retinal care from managing late-stage damage to proactive vision preservation, offering an outpatient procedure that integrates into regular eye care. Maculaser plans to bring the treatment into clinical practice to benefit millions of patients worldwide.
ZEISS Medical Technology has received approval from Mexico's COFEPRIS for two ophthalmic surgical devices: the ARTEVO 850 microscope and MICOR 700 lens removal device. Both technologies are compatible with ZEISS's latest cataract workflow systems. The ARTEVO 850 is a 3D heads-up ophthalmic microscope offering true colour imaging and a nearly 60% increase in depth of field. The MICOR 700 is the first handheld lens removal device with ultrasound-free operation, using ZEISS's non-ultrasonic lens extraction procedure to minimise risk to surrounding eye structures. The products will be showcased at the Mexican Congress of Ophthalmology in Monterrey from 30 May to 3 June 2026. ZEISS Medical Technology generated revenue of €2,066.1 million in fiscal year 2023/24.
Hypervision Surgical, a UK-based pioneer in real-time hyperspectral imaging for surgery, has raised £17 million in an oversubscribed Series A round led by Heal Capital. Angelini Ventures participated alongside IP Group and Daycrest, with Angelini Ventures Managing Director Tanja Dowe joining the board. The King's College London spin-out has developed the Hyperspectral Intelligence platform, which combines hyperspectral sensing with AI-driven analytics to provide real-time, quantitative insights into tissue physiology during surgery. The technology captures information beyond what conventional surgical cameras can perceive, potentially improving intraoperative decision-making and reducing complications. The funding will support commercial deployment, clinical adoption and development of next-generation hyperspectral sensing technology. The company's HYPERSNAP system is certified in the UK and cleared by the US FDA.